Olodaterol (CAS 868049-49-4)
Alternate Names:
6-Hydroxy-8-[(1R)-1-hydroxy-2-[[2-(4-methoxyphenyl)-1,1-dimethylethyl]amino]ethyl]-2H-1,4-benzoxazin-3(4H)-one; BI 1744
CAS Number:
868049-49-4
Molecular Weight:
386.44
Molecular Formula:
C21H26N2O5
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Olodaterol is a long-acting beta-adrenoceptor agonist (LABA) characterized by its ability to selectively target and activate beta2-adrenergic receptors. Its mechanism of action hinges on stimulating intracellular adenylate cyclase, an enzyme responsible for converting adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP). The specificity and efficiency of olodaterol in targeting beta-2 adrenergic receptors are of interest in biochemical research, where the understanding of receptor-ligand interactions and signaling pathways is crucial. Studies on olodaterol and similar compounds can provide insights into the structural requirements for receptor activation and the pharmacodynamics involved in the selective targeting of receptor subtypes. Its role in research extends beyond our understanding of adrenergic receptor signaling pathways.
Olodaterol (CAS 868049-49-4) References
- Tiotropium sustains the anti-inflammatory action of olodaterol via the cyclic AMP pathway. | Costa, L., et al. 2014. Pulm Pharmacol Ther. 27: 29-37. PMID: 24269928
- Olodaterol attenuates citric acid-induced cough in naïve and ovalbumin-sensitized and challenged guinea pigs. | Wex, E. and Bouyssou, T. 2015. PLoS One. 10: e0119953. PMID: 25781609
- The long-acting β2 -adrenoceptor agonist olodaterol attenuates pulmonary inflammation. | Wex, E., et al. 2015. Br J Pharmacol. 172: 3537-47. PMID: 25824824
- Olodaterol and vilanterol detection in sport drug testing. | Chundela, Z. and Große, J. 2015. Drug Test Anal. 7: 980-2. PMID: 26593301
- Pharmacological characterization of the interaction between tiotropium and olodaterol administered at 5:5 concentration-ratio in equine bronchi. | Calzetta, L., et al. 2017. COPD. 14: 526-532. PMID: 28745522
- Long-term cost-effectiveness of the fixed-dose combination of tiotropium plus olodaterol based on the DYNAGITO trial results. | Hoogendoorn, M., et al. 2019. Int J Chron Obstruct Pulmon Dis. 14: 447-456. PMID: 30863045
- Pharmacological characterization of the interaction between tiotropium bromide and olodaterol on human bronchi and small airways. | Calzetta, L., et al. 2019. Pulm Pharmacol Ther. 56: 39-50. PMID: 30876907
- No Evidence of Off-label Use of Olodaterol and Indacaterol in Denmark, France, and the Netherlands: A Drug Utilization Study. | Rebordosa, C., et al. 2020. Sci Rep. 10: 586. PMID: 31953521
- No Influence on Cardiac Arrhythmia or Heart Rate from Long-Term Treatment with Tiotropium/Olodaterol versus Monocomponents by Holter ECG Analysis in Patients with Moderate-to-Very-Severe COPD. | Andreas, S., et al. 2020. Int J Chron Obstruct Pulmon Dis. 15: 1945-1953. PMID: 32848380
- A Post Hoc Holter ECG Analysis of Olodaterol and Formoterol in Moderate-to-Very-Severe COPD. | Andreas, S., et al. 2020. Int J Chron Obstruct Pulmon Dis. 15: 1955-1965. PMID: 32848381
- A comparison of tiotropium/olodaterol vs tiotropium alone in terms of treatment effect for chronic obstructive pulmonary disease: A meta-analysis: Retraction. | . 2020. Medicine (Baltimore). 99: e22420. PMID: 32957422
- Tiotropium/Olodaterol treatment reduces cigarette smoke extract-induced cell death in BEAS-2B bronchial epithelial cells. | Chen, CH., et al. 2020. BMC Pharmacol Toxicol. 21: 74. PMID: 33129351
- Olodaterol exerts anti-inflammatory effects on COPD airway epithelial cells. | Yang, N., et al. 2021. Respir Res. 22: 65. PMID: 33622325
- Cost-effectiveness of the fixed-dose combination tiotropium/olodaterol versus tiotropium monotherapy or a fixed-dose combination of long-acting β2-agonist/inhaled corticosteroid for COPD in Finland, Sweden and the Netherlands: a model-based study. | Hoogendoorn, M., et al. 2021. BMJ Open. 11: e049675. PMID: 34348953
- Cardiovascular events and all-cause mortality in patients with chronic obstructive pulmonary disease using olodaterol and other long-acting beta2-agonists. | Rebordosa, C., et al. 2022. Pharmacoepidemiol Drug Saf. 31: 827-839. PMID: 35320605
Activator of:
RAMP2.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Olodaterol, 5 mg | sc-478192 | 5 mg | $317.00 | |||
Olodaterol, 10 mg | sc-478192A | 10 mg | $580.00 | |||
Olodaterol, 25 mg | sc-478192B | 25 mg | $1254.00 | |||
Olodaterol, 100 mg | sc-478192C | 100 mg | $3584.00 |